Our client, a global biopharma company, aspired to develop a 10-year strategy
to expand sustainable access to their innovative medicines in low- and middle-income countries (LMICs).
With a commitment to global health equity, they set out to double both their geographical footprint and the number of patients treated in these regions.
Following our assessment of the relevant LMICs,
we determined where profitable access is feasible and where not-for-profit access is the preferable solution.
Our team then developed dedicated strategies based on the client’s core company values, internal resources, and deep business analyses, identifying tangible actions to unlock LMIC market potential and improve medicine accessibility simultaneously. We built a commercialization roadmap for immediate roll-out with clear goals and outlined key initiatives.
The outcome for our client was a clear vision and direction to progress toward the end goal
of expanding access in LMICs, ensuring alignment across all functions and regions.
By expanding their presence in these markets, our client is not only strengthening its long-term business growth but also demonstrating a clear commitment to social responsibility, contributing to global health equity and addressing critical healthcare disparities.
お問い合わせ
サイモン・クチャーのエキスパートがいつでもご相談に応じます。お気軽にお問い合わせください。